MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

Consensus Ratings for Catabasis Pharmaceuticals (NASDAQ:CATB) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.75 (457.60% upside)

Analysts' Ratings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016WedbushReiterated RatingOutperform$27.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016OppenheimerReiterated RatingOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Citigroup Inc.Lower Price TargetBuy$21.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2016Q415($0.69)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.63)($0.60)($0.62)
Q2 20162($0.65)($0.61)($0.63)
Q3 20162($0.67)($0.61)($0.64)
Q4 20162($0.69)($0.61)($0.65)
Q1 20171($0.73)($0.73)($0.73)
Q2 20171($0.80)($0.80)($0.80)
Q3 20171($0.91)($0.91)($0.91)
Q4 20171($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)
Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Catabasis Pharmaceuticals (NASDAQ:CATB)
DateHeadline
06/20/16 03:02 PMCATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 09:27 AMCatabasis Pharmaceuticals (NASDAQ:CATB) target price dropped to $8 as recorded today by Citigroup
06/20/16 07:00 AMCatabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference - [Business Wire] - Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that edasalonexent will be featured in an oral presentation and a poster presentation at the upcoming 2016 Parent Project Muscular Dystrophy Annual Connect Conference being held on Sunday, June 26 – Wednesday, June 29, 2016 at the Renaissance Orlando at Sea World Hotel in Orlando, FL.
06/08/16 09:29 PMCatabasis Pharma (CATB) Announces CAT-2054 Phase 2a Missed Primary Endpoint in Hypercholesterolemia
06/08/16 09:29 PMDrug Data Deals a Blow to Catabasis Pharmaceuticals Inc (CATB)
06/08/16 05:05 PMCatabasis Pharmaceuticals, Inc. :CATB-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/08/16 11:09 AM5 Stocks That Are Getting Battered and Bruised Today -
06/08/16 07:28 AMCatabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar ...
06/07/16 08:41 PMCatabasis shares halted as cholesterol drug misses study goal
06/07/16 04:19 PMCatabasis shares fall 50% as cholesterol drug misses study goal -
06/07/16 03:53 PMCatabasis Pharma's cholesterol drug fails mid-stage study -
06/07/16 03:48 PMCatabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line results from its Phase 2a clinical ...
05/25/16 01:58 PMTarget Check and Stock Performance Recap Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Wall Street Hints and News - Target Check and Stock Performance Recap Catabasis Pharmaceuticals Inc (NASDAQ:CATB)Wall Street Hints and NewsIn recent session activity, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares have traded +12.77%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/25/16 01:58 PMEarnings Review and Stock Rundown for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Wall Street Hints and News - Earnings Review and Stock Rundown for Catabasis Pharmaceuticals Inc (NASDAQ:CATB)Wall Street Hints and NewsEarnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to post quarterly EPS of $-0.64. The company is expected to next publish earnings on or ...and more »
05/22/16 01:57 PMCatabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT ... - Business Wire (press release) - Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT ...Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 as a potential treatment for nonalcoholic ...and more »
05/22/16 01:57 PMRevenue Update on Catabasis Pharmaceuticals Inc(NASDAQ:CATB) - Trade Calls - Revenue Update on Catabasis Pharmaceuticals Inc(NASDAQ:CATB)Trade CallsCatabasis Pharmaceuticals Inc(NASDAQ:CATB) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Earnings per share were $-0.61. Analysts had estimated an EPS of $-0.64. In a different ...Is it Time to Cash in Profits on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)Franklin Independentall 2 news articles »
05/21/16 11:53 AMCatabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced positive pre-clinical data supporting CAT-2054 ...
05/20/16 12:04 PMCATABASIS PHARMACEUTICALS INC Financials -
05/16/16 07:32 AMCatabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment ...
05/16/16 07:32 AMCatabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016 - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that ...
05/13/16 01:06 PMEdited Transcript of CATB earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:27 PMCatabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights - [at noodls] - -- Edasalonexent (CAT-1004) as a Potential Treatment for Duchenne Muscular Dystrophy (DMD): MoveDMD Part B (Phase 2) Trial Initiated Following Positive Safety, Tolerability, Pharmacokinetic and NF-kB Biomarker ...
05/12/16 03:12 PMCatabasis Pharmaceuticals posts 1Q loss -
05/12/16 03:03 PMCATABASIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/12/16 06:07 AMQ1 2016 Catabasis Pharmaceuticals Inc Earnings Release - After Market Close -
05/11/16 01:34 PMConsensus Rating Review for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - B.O.D.Y Confidential - Consensus Rating Review for Catabasis Pharmaceuticals Inc (NASDAQ:CATB)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/11/16 01:34 PMCatabasis Pharmaceuticals Inc (CATB) Scheduled to Post Earnings on Thursday - Washington News Wire - Washington News WireCatabasis Pharmaceuticals Inc (CATB) Scheduled to Post Earnings on ThursdayWashington News WireCatabasis Pharmaceuticals logo Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will announce its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter.Latest Analyst Reports On Catabasis Pharmaceuticals, Inc.Risers & Fallersall 2 news articles »
05/07/16 01:06 PMBroker Roundup For Catabasis Pharmaceuticals, Inc. (CATB) - Share Trading News - Broker Roundup For Catabasis Pharmaceuticals, Inc. (CATB)Share Trading News07/20/2015 – Cowen began new coverage on Catabasis Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 30 price target on the stock. The share price of Catabasis Pharmaceuticals, Inc. (CATB) was down -4.91% during ...Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Analyst Rating PerspectiveThe Postall 4 news articles »
05/04/16 01:00 PMAverage Analyst Rating for Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - B.O.D.Y Confidential - Average Analyst Rating for Catabasis Pharmaceuticals Inc (NASDAQ:CATB)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 01:21 PMBroker Outlook For Catabasis Pharmaceuticals, Inc. (CATB) - Share Trading News - Broker Outlook For Catabasis Pharmaceuticals, Inc. (CATB)Share Trading NewsCatabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) ...
04/29/16 01:27 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB) ABR of 1 - RealistInvestor.com - Catabasis Pharmaceuticals Inc (NASDAQ:CATB) ABR of 1RealistInvestor.comAnalysts have a buy call on Catabasis Pharmaceuticals Inc (NASDAQ:CATB) stock. As of 2016-04-28, the stock has an ABR of 1. This rating comes on a scale of 1-5, where one makes a strong buy call, and 3 indicates Strong Sell. This ABR computation is ...and more »
04/28/16 07:19 AMCatabasis Pharmaceuticals to Report First Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, May 12 - [at noodls] - The Company will Host a Conference Call at 4:30pm ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2016-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report ...
04/27/16 01:54 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Rating Recap - B.O.D.Y Confidential - Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Rating RecapB.O.D.Y ConfidentialShares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/27/16 01:54 PMStock Falling Today: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - The Post - Stock Falling Today: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)The PostCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) was a top loser in today's session as the company saw shares drop -8.50% on the day at the time of writing. Stocks whose market prices drop the most during the trading day are bluntly referred to as losers.
04/24/16 12:49 PMAfter Last Week What Do Analysts Think Of Catabasis Pharmaceuticals, Inc. (CATB) - Share Trading News - Mas Market NewsAfter Last Week What Do Analysts Think Of Catabasis Pharmaceuticals, Inc. (CATB)Share Trading News07/20/2015 – Cowen began new coverage on Catabasis Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 30 price target on the stock. The share price of Catabasis Pharmaceuticals, Inc. (CATB) was down -0.99% during ...Zacks: Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Given $28.33 Average Price Target by AnalystsMas Market Newsall 21 news articles »
04/21/16 01:42 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Rating Recap - The Post - Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Rating RecapThe PostShares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/19/16 10:35 AM​Another Duchenne-focused biotech joins the Boston area biotech hub -
04/16/16 12:56 PMCatabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Short Interest Increased By 15.76% - RiversideGazette.com - Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Short Interest Increased By 15.76%RiversideGazette.comThe short interest to Catabasis Pharmaceuticals Incorporated's float is 5.79%. The stock increased 1.35% or $0.07 during the last trading session, hitting $5.25. About 15,048 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined ...and more »
04/16/16 12:56 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB): Quick Look at Earnings - News Tribune - News TribuneCatabasis Pharmaceuticals Inc (NASDAQ:CATB): Quick Look at EarningsNews TribuneWhen Catabasis Pharmaceuticals Inc (NASDAQ:CATB) issues their next quarterly report on or near 2016-06-01, Wall Street analysts are predicting they will report earnings per share of $-0.64. This consensus EPS number is provided by Zacks Research, ...and more »
04/15/16 01:48 PMCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Analyst Recommendation Outlook - Clinton Financial - Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 3 analysts providing ratings for Catabasis Pharmaceuticals Inc (NASDAQ:CATB). 3 have given the stock a “Strong Buy”, ...and more »
04/14/16 01:32 PMAnalyst Coverage: Catabasis Pharmaceuticals, Inc. (CATB) - Risers & Fallers - Analyst Coverage: Catabasis Pharmaceuticals, Inc. (CATB)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Catabasis Pharmaceuticals, Inc. (CATB). The latest broker reports which are currently outstanding on Thursday 14th of April state 2 analysts have a rating of “strong buy”, ...and more »
04/13/16 01:47 PMCatabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Sellers Covered 3.35% of Their Shorts - Stock Caller - Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Sellers Covered 3.35% of Their ShortsStock CallerThe short interest to Catabasis Pharmaceuticals Incorporated's float is 5%. The stock increased 4.04% or $0.2 during the last trading session, hitting $5.15. About 19,843 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined ...and more »
04/13/16 01:47 PMView on Ratings Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Business Standard Tribune - View on Ratings Catabasis Pharmaceuticals Inc (NASDAQ:CATB)Business Standard TribuneUsing a scale from 1 to 5, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has a rating of 1 on the stock. A score of 1 or 2 indicates a Buy rating, and a score of 4 or 5 indicates a Sell rating. A 3 would indicate a Hold. This consensus number is made up ...and more »
04/12/16 01:23 PMBroker Outlook For The Week Ahead Catabasis Pharmaceuticals, Inc. (CATB) - Share Trading News - Broker Outlook For The Week Ahead Catabasis Pharmaceuticals, Inc. (CATB)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Catabasis Pharmaceuticals, Inc. (CATB). The most recent broker reports which have been released note that 2 analysts ...and more »
04/12/16 01:22 PMCatabasis Pharmaceuticals Initiates Part B of the MoveDMDSM Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy - They also announced positive biomarker results from Part A of the trial.” Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that dosing of the first patient has been initiated in Part B of the ...
04/11/16 03:02 PMCATABASIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
04/11/16 01:42 PMLatest Analyst Reports On Catabasis Pharmaceuticals, Inc. - Risers & Fallers - Latest Analyst Reports On Catabasis Pharmaceuticals, Inc.Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Catabasis Pharmaceuticals, Inc. (CATB). The latest broker reports which have been released state 2 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts ...and more »
04/09/16 12:58 PMWill Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Surprise Analysts This Quarter? - Stocks Daily - Will Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Surprise Analysts This Quarter?Stocks DailyCatabasis Pharmaceuticals Inc (NASDAQ:CATB) posted earnings of $-0.63 per share for the last fiscal quarter which ended on 2015-12-31. The reported number was $0.08 away from the Zacks consensus estimate which was calculated just prior to the ...and more »
04/08/16 01:28 PMIs Catabasis Pharmaceuticals Inc (NASDAQ:CATB) a Consensus Buy? - Clinton Financial - Is Catabasis Pharmaceuticals Inc (NASDAQ:CATB) a Consensus Buy?Clinton FinancialEquity research firms covering public U.S companies have a workforce of analysts dedicating their time covering the most popular stocks. Their reports are delivered to institutional investors in order to help make investment decisions. The information ...and more »
04/08/16 01:28 PMCatabasis Pharmaceuticals, Inc. (CATB) Updated Broker Ratings - Risers & Fallers - Catabasis Pharmaceuticals, Inc. (CATB) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Catabasis Pharmaceuticals, Inc. (CATB). According to the latest broker reports outstanding on Friday 8th of April, 2 analysts have a rating of “strong buy”, 1 ...
About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CATB
  • CUSIP:
Key Metrics:
  • Previous Close: $4.00
  • 50 Day Moving Average: $5.22
  • 200 Day Moving Average: $5.84
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $62.73M
  • Current Quarter EPS Consensus Estimate: $-2.52 EPS
Additional Links:
Catabasis Pharmaceuticals (NASDAQ:CATB) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha